De Philippis, Chiara http://orcid.org/0000-0002-7738-997X
Zucchinetti, Cristina
Mannina, Daniele
Krampera, Mauro
Zinzani, Pier Luigi http://orcid.org/0000-0002-2112-2651
Chiappella, Annalisa http://orcid.org/0000-0002-2977-0098
di Rocco, Alice
Orcioulo, Enrico
Tisi, Maria Chiara
Pistolese, Flavio
Giordano, Laura
Santoro, Armando
Bramanti, Stefania http://orcid.org/0000-0002-4117-7991
Article History
Received: 13 September 2023
Revised: 5 December 2023
Accepted: 9 January 2024
First Online: 25 January 2024
Competing interests
: AC: Advisory Board: Ideogen, Roche, Takeda. Speakers’ Bureau: Astrazeneca, Gilead-Sciences, Janssen-Cilag, Novartis. PLZ: Consulting or Advisory Role: Sanofi, Verastem, Celltrion, Gilead Sciences, Janssen-Cilag, Bristol-Myers Squibb, Servier, Sandoz, MSD, Immune Design, Celgene, Portola Pharmaceuticals, Roche, EUSA Pharma, Kyowa Hakko Kirin. Speakers’ Bureau: Verastem, Celltrion, Gilead Sciences, Janssen-Cilag, Bristol-Myers Squibb, Servier, Sandoz, MSD, Immune Design, Celgene, Portola Pharmaceuticals, Roche, EUSA Pharma, Kyowa Hakko Kirin. AS: Consulting or Advisory Role: Bristol-Myers Squibb, Servier, Gilead Sciences, Pfizer, Eisai, Bayer, MSD. Speakers’ Bureau: Takeda, Roche, AbbVie, Amgen, Celgene, AstraZeneca, ArQule, Lilly, Sandoz, Novartis. CDP: Speakers’ Bureau: Novartis, Gilead. DM: Speakers’ Bureau: Novartis, Gilead. SB: Speakers’ Bureau: Novartis, Gilead, Astra-Zeneca, Roche, Kiova, Bristol-Myers-Squibb.